Peginterferon beta-1a is an interferon beta used to treat relapsing forms of multiple sclerosis. Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body.
- Mechanism
- Curator reviewed · 3 references
The mechanism by which peginterferon beta-1a exerts its effects in patients with multiple sclerosis is unknown, however, it likely exerts its therapeutic actions by reducing inflammation. Through the binding of IFN-beta to its receptor, a cascade of transcriptional events occur, decreasing the inflammation that normally results in the progression of MS. Immune cells are the most likely target of therapeutic effects exerted by IFN-beta.
- Primary indication
- Peginterferon beta-1a is indicated for the treatment of adult patients with relapsing forms of MS, including relapsing-remitting disease, clinically isolated syndrome, and active progressive secondary disease.Curator reviewed · 1 structured indication
- Formula / weight
- 22500.0 Da (predicted)
- First approval
- Canada, 2015 · United States, 2014 · European Union, 2016
- Also known as
- PEG IFN-beta-1a · Polyethylene glycol-interferon beta-1a
- Code names
- BIIB-017
- Brand names
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with Peginterferon beta-1a, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account